@entity1 with @entity2175 have a twofold to fourfold increased risk of dying from the complications of @entity65 . @entity731 and vascular @entity715 are major contributors. The increased risk is present before fasting @entity4854 is seen. These individuals often have a sedentary life-style, poor physical conditioning, @entity2690 resistance, @entity28 , @entity101 , @entity2299 , and a prothrombotic state. @entity4854 is then added to these risk markers. Microalbuminuria may precede @entity4854 in @entity2175 , occurs in 30% to 40% of these individuals after @entity6 is established, and is a predictor of cardiovascular events. Early intervention in high-risk individuals may delay or prevent fasting @entity4854 . An all-inclusive approach that focuses on early risk factor (or marker) identification and management to prevent or delay accelerated @entity731 and @entity715 in @entity2175 is an attractive strategy. However, the database to support this strategy is limited. In particular, large-scale prospective trial data are not available to support the concept of intensive glycemic regulation to prevent progression of @entity66 in @entity2175 . This is in contrast to the situation regarding microvascular disease of the eyes and kidneys. Recently, indirect data of a correlative nature have emerged, and short- and long-term prospective trials at early and late stages of @entity2175 are now being reported. These studies are analyzed and interpreted in this report. In contrast, the database to support an intensive antiplatelet regimen to prevent vascular @entity715 events in @entity1 with @entity2175 is large, and these studies are reviewed. They are of a type and magnitude to allow definite recommendations for aspirin therapy in @entity2175 . Aggressive therapy directed at @entity101 , @entity407 , and elevated urinary albumin in @entity1 with @entity2175 appears to be indicated. Increased attention to the multifactorial aspects of treatment of the type II @entity6 @entity1 is needed. Our present challenge is to translate these findings for @entity1 and primary health care providers so that effective actions may be implemented.

Multifactorial aspects of the treatment of the type II @entity6 XXXX .

@entity1 :: ('9606', 'Species') :: ['patient', 'patients', 'people', 'People'] @entity2175 :: ('MESH:D003924', 'Disease') :: ['type II diabetes'] @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity28 :: ('MESH:D009765', 'Disease') :: ['centripetal obesity'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'diabetic'] @entity66 :: ('MESH:D004194', 'Disease') :: ['macrovascular disease'] @entity2690 :: ('3630', 'Gene') :: ['insulin'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis', 'Atherosclerosis'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia', 'Chronic hyperglycemia'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic']
@entity1 :: (9606,Species) :: ['patient']
